Transforming
Lyme Disease Diagnosis

LymeSeek is the first clinically accurate diagnostic test for all stages of Lyme disease, including early stage.

>90%

Accuracy

Across All Stages

Improving detection when it matters most.

700+

Clinical Samples Evaluated

Including samples from early Lyme infection.

FDA

Clinical Trial Starting

Q3 2026

Pivotal trial underway to support regulatory clearnace.

12M+

Lyme Tests

Performed Annually

In the United States

and Europe.

$750M

Addressable Market Opportunity

Strong market need.

Compelling value.

Improved Early Detection

Detects more infections during the earliest stage, when treatment is most effective.

Proprietary biomarker panel captures a broader immune response to Borrelia burgdorferi.

Machine learning algorithm enhances accuracy and reduces false results.

Designed for seamless integration into existing laboratory infrastructure.

Download our one-pager to explore the science, clinical validation, market opportunity, and roadmap behind LymeSeek™.